Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance Aug 2, 2023 07:30AM
Repligen to Report Second Quarter 2023 Financial Results Jul 19, 2023 07:30AM
Repligen Corporation to Present at Upcoming Investor Conferences May 31, 2023 07:30AM
Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance May 2, 2023 07:30AM
Repligen to Report First Quarter 2023 Financial Results Apr 18, 2023 07:30AM


Mar 14, 2023 07:30AM Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
Feb 22, 2023 07:30AM Repligen Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 9, 2023 07:31AM Repligen (RGEN) Appoints Martin D. Madaus to Board of Directors
Feb 9, 2023 07:30AM Repligen Appoints Martin D. Madaus to Board of Directors
Feb 8, 2023 07:30AM Repligen to Report Fourth Quarter and Full Year 2022 Financial Results
Jan 3, 2023 07:30AM Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
Nov 8, 2022 07:30AM Repligen Corporation to Present at Upcoming Investor Conferences
Nov 1, 2022 07:30AM Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
Nov 1, 2022 07:03AM Repligen (RGEN) Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands
Nov 1, 2022 07:00AM Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands
Oct 12, 2022 07:30AM Repligen to Report Third Quarter 2022 Financial Results
Sep 19, 2022 04:02PM Repligen (RGEN) Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement
Sep 19, 2022 04:01PM Repligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement
Aug 24, 2022 07:30AM Repligen To Host Investor Day 2022
Aug 2, 2022 07:30AM Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance
Jul 19, 2022 07:30AM Repligen to Report Second Quarter 2022 Financial Results
May 26, 2022 04:32PM Repligen (RGEN) Appoints Konstantin Konstantinov to its Board
May 26, 2022 04:30PM Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors
May 25, 2022 07:30AM Repligen Corporation to Present at Upcoming Investor Conferences
Apr 27, 2022 07:30AM Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
Apr 13, 2022 07:30AM Repligen to Report First Quarter 2022 Financial Results
Mar 18, 2022 07:30AM Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
Feb 17, 2022 07:30AM Repligen Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 15, 2022 07:30AM Repligen Launches AAV Affinity Resins for Gene Therapy Purification
Feb 11, 2022 07:30AM Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference
Feb 3, 2022 09:30AM Repligen to Report Fourth Quarter and Full Year 2021 Financial Results
Dec 30, 2021 07:30AM Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
Nov 12, 2021 07:30AM Repligen Corporation to Present at Upcoming Investor Conferences
Nov 11, 2021 07:26PM IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS
Nov 5, 2021 07:30AM Repligen Releases Inaugural Sustainability Report
Oct 28, 2021 07:30AM Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
Oct 14, 2021 07:30AM Repligen to Report Third Quarter 2021 Financial Results
Sep 16, 2021 07:41AM Repligen (RGEN) to Acquire Avitide for Approximately $150 Million
Sep 16, 2021 07:40AM Repligen Announces Agreement to Acquire Avitide Inc.
Apr 16, 2014 09:24AM Pre-Open Stock Movers 4/16: (ZLCS) (SODA) (YHOO) Higher; (ASML) (CSX) (TWTR) Lower (more...)